ScholarWorks@Korea University College of Medicine: Kim, Dong-Sik

Detailed Information

Kim, Dong-Sik (김동식)

Anam Hospital (Department of Hepato-Biliary-Pancreatic Surgery, Anam Hospital)

Research Area: 간이식, 간세포암, 간재생, Liver Transplantation, Hepatocellular carcinoma, Liver Regeneration

Tel 02-920-6620
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Liver transplantation:11||Hepatocellular carcinoma:10||Hepatectomy:8||Treatment outcome:5||hepatocellular carcinoma:4||Prognosis:4||Survival:4||hepatitis B virus:4||Recurrence:3||Carcinoma:3||Middle hepatic vein:3||liver transplantation:3||Chemotherapy:2||Hepatic venous congestion:2||renal dysfunction:2||overall survival:2||Terlipressin:2||living donor liver transplantation:2||Postoperative complications:2||survival:2||Living donor liver transplantation:2||Liver Transplantation:2||morbidity:2||Distal pancreatectomy:2||hepatectomy:2||hepatocellular:2||Portal vein:2||hepatocyte nuclear factor:2||Hepatic stellate cells:2||Pancreatic neoplasms:2||Resection:2||Complication:2||Liver resection:2||portal pressure:2||Metastasis:2||Risk factors:2||Surgery:2||prognosis:2||DIAGNOSIS:1||DONOR LIVERTRANSPLANTATION:1||Da Vinci SP system:1||Deceased donor liver transplantation:1||Defibrotide:1||Diabetes:1||Diagnosis:1||Digital microfluidics:1||Diseasefree survival:1||Donor:1||Donor safety:1||Donor selection:1||Droplet transport:1||Ducttomucosa anastomosis:1||Early allograft dysfunction:1||Early diagnosis:1||Efficacy:1||Electrowetting:1||Entecavir:1||Expanding the donor pool:1||Extended right lobe graft:1||F18FDG PET/CT:1||Failure:1||Fineneedle aspiration:1||Fistula:1||Fluid therapy:1||GRAFT:1||Gallbladder:1||Gastrointestinal stromal tumor:1||Gene signature:1||Genomics:1||Grade:1||Guideline:1||Guidelines:1||HBx:1||Hemoglobin concentration measurement:1||Hepatic artery:1||Hepatic tumor:1||Hepatic veins:1||Hepatitis B Immunoglobulin:1||Hepatitis B Virus:1||Hepatitis B virus:1||Hepatocellular Carcinoma:1||Hepatocellular carcinoma (HCC):1||Hepatocyte:1||Hepatocyte nuclear factor 1alpha:1||Hepatocytes:1||Hepatospheres:1||Heterospheres:1||Hilar cholangiocarcinoma:1||Humans:1||INFLOW:1||Immunohistochemistry:1||Immunosuppression:1||Immunosuppression therapy:1||Immunosuppressive agents:1||Incidence:1||Indication:1||Intestinal obstruction:1||Intraductal papillary neoplasm of the bile duct:1||Intraepithelial neoplasm:1||Intrahepatic bile duct:1||Intrahepatic cholangiocarcinoma:1||Intrahepatic cholestasis:1||LED:1||Laparoscopic:1||Large cell neuroendocrine carcinoma:1||Learning curve:1||Left liver graft:1||Left lobe graft:1||Liver Neoplasms:1||Liver abscess:1||Liver failure:1||Liver metastasis:1||Liver neoplasm:1||Liver regeneration:1||Liver transplantation program:1||Living donor Liver transplantation:1||Lymphatic Diseases:1||MALT lymphoma:1||MODULATION:1||Magnetic resonance imaging:1||Malignant mesothelioma:1||Management:1||Marginal organs:1||Mesothelioma:1||Metastatic hepatocellular carcinoma:1||Microfluidic:1||Milan criteria:1||Minimally invasive surgery:1||Modified right lobe graft:1||Molecular targeted therapy:1||Multidetectorrow computed tomography:1||Multidisciplinary:1||Nacetylcysteine:1||Nafamostat mesilate:1||Neoplasm metastasis:1||Neurofibromatosis type 1:1||Neurologic:1||Nonanatomic resection:1||Nutritional support:1||Operative outcomes:1||Organ:1||Organ transplantation:1||Outcome:1||Outcomes:1||Overall survival:1||PORTALHYPERTENSION:1||Pancreatic cyst:1||Pancreatic leakage:1||Pancreaticoduodenectomy:1||Pancreaticojejunostomy:1||Parenteral nutrition:1||Parotid gland:1||Phytobezoar:1||Portal flow steal:1||Portal modulation:1||Prediction:1||Primary hepatic lymphoma:1||Principal component analysis:1||Prolongedrelease tacrolimus:1||Radical resection:1||Renal dysfunction:1||Renal insufficiency:1||Republic of Korea:1||Right anterior segmentectomy:1||Right hepatic vein:1||Risk factor:1||Robotic:1||Robotic singlesite:1||RouxenY:1||SPLENECTOMY:1||SPLENIC ARTERY LIGATION:1||Safety:1||Salvage Liver transplantation:1||Serum amyloid A protein:1||Shear stress:1||Singleplate configuration:1||Singleport:1||Smallforsize graft:1||Smallforsize syndrome:1||Smallforsizesyndrome:1||Somatostatin:1||Sorafenib:1||Spectrophotometry:1||Spheroid:1||Splenorenal shunt:1||Stability:1||Subtype:1||Surgical anastomosis:1||Survival analysis:1||Synchronous:1||Tacrolimus:1||Tenofovir:1||Therapeutic equivalence:1||Thrombosis:1||Total nutrient admixtures:1||Transplantation:1||Triple negative breast cancer:1||Tumor Marker:1||Tumor biology:1||Tumor marker:1||Tumor thrombosis:1||Ultrasonography:1||Vascular complication:1||Venoocclusive disease:1||Viral Hepatitis:1||animal model:1||bile duct resection:1||biliary tract neoplasm:1||cFLIP:1||cancerspecific survival (CSS):1||catheter ablation:1||cholangiocarcinoma:1||chronic kidney disease:1||cirrhosis:1||coculture:1||drug resistance:1||end stage liver disease:1||enhanced recovery after surgery:1||fibrosis:1||gadoxetic acidenhanced MRI:1||graft outcomes:1||graftversushost disease:1||gross morphology:1||hemoglobin:1||hepatic stellate cell:1||hepatotoxicity:1||human leukocyte antigen:1||hypervascular hepatocellular carcinoma:1||immunosuppression:1||immunosuppressive drugs:1||infiltrative type:1||interferongamma:1||intraductal papillary mucinous neoplasm of the pancreas:1||intraepithelial neoplasm:1||jaundice:1||laparoscopic left hepatectomy:1||lipidomics:1||liver failure:1||liver generation:1||liver regeneration:1||liver resection:1||living donors:1||lymph node metastasis:1||mTOR inhibitor:1||magnetic resonance imaging:1||microfluidic:1||mortality:1||mycophenolate mofetil:1||neoplasm invasion:1||nodular type:1||nonhomozygous:1||nucleos(t)ide analog:1||open left hepatectomy:1||outcomes:1||overall survival (OS):1||pancreatectomy:1||perihilar cholangiocarcinoma:1||peripheral intrahepatic cholangiocarcinoma:1||portal flow:1||portal inflow modulation:1||portal modulation:1||portal vein invasion (PVI):1||postoperative complications:1||preinvasive carcinoma:1||prognostic efficacy:1||radiofrequency ablation:1||recurrence:1||recurrencefree survival:1||related body regions:1||reverse transcription:1||somatostatin:1||spheroid:1||surgery:1||surgical resection:1||survival analysis:1||tacrolimus:1||tenofovir disoproxil fumarate (TDF):1||terlipressin:1||thrombectomy:1||timeconditional propensity score:1||transcriptional control:1||transplant donor:1||tripartite motifcontaining protein 21:1||tumor staging:1||문맥혈류 steal:1||비신단락:1||.:1||생체간이식:1||1year recurrence:1||AJCC 8th staging system:1||AP:1||Adenocarcinoma, Mucinous:1||Adenoma, liver cell:1||Adenosquamous:1||Adiponectin:1||Adjuvant chemotherapy:1||Allinone system:1||Anastomosis:1||Anatomic resection:1||Anatomic variations:1||Antiadhesive agent:1||Antiviral Agent:1||Artificial intelligence:1||Asia:1||Beta catenin:1||Bile Ducts, Extrahepatic:1||Bile duct neoplasms:1||Bile leakage:1||Biliary:1||Biomarker:1||Biomarkers:1||Blood analysis:1||Brain Dead:1||CMOS image sensor:1||COMPLICATIONS:1||CT HA:1||Carcinogenesis:1||Cell cycle:1||Choledochoduodenal:1||Chronic hepatitis B:1||Chronic liver disease:1||Coculture:1||Colorectal neoplasms:1||Concave microwell array:1||Constriction:1||

STATISTICS: Total View :13,966,270; Today View :14,223

RSS_1.0 RSS_2.0 ATOM_1.0

73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE